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his study was conducted to compare the bioavailability of two branded formulations of 
aceclofenac and to evaluate their pharmacokinetic behavior. For bioequivalence study of two 
formulations of aceclofenac; drug A and drug B were administered to 18 healthy human 
volunteers using a two-treatment, two-way cross over study design in a randomized fashion. For the 
determination of aceclofenac plasma concentration, validated HPLC method with UV-visible detector, 
20 µl injecting loop and C18 analytical column were used. The lower limit of detection is 0.0195µg/ml 
and quantitation range is 0.039, 0.078, 0.156, 0.312, 0.625, 1.25, 2.5, 5, 10 and 20µg/ml. Different 
pharmacokinetic parameter were determined including Tmax, T1/2, Cmax, AUC0-t, AUC0-∞, vd, ke for 
two formulations of aceclofenac in plasma. After log-transformation of plasma data for bioequivalence 
Cmax, AUC0-t and AUCt-∞ were tested. The Cmax values of 7.69 ± 0.14221µg/ml and 6.82 ± 
0.13411µg/ml were attained in 3.14 ± 0.0801 h and 2.94 ± 0.1878 h for drug A and Drug B, 
respectively. AUC0-t was 45332.79 ±  2096.770µg.h/ml and 43842.56 ±  1046.954µg.h/ml, 
respectively. AUC0-∞ was 45329.97±2138.871µg.h/ml and 43589.97 ± 1039.78 µg.h/ml for drug 
A and Drug B, respectively. The t1/2 values were found to be 3.14 ± 0.080 h and 3.01 ± 0.024 h for 
drug A and Drug B. 
Keywords: Bioequivalence, Pharmacokinetics; HPLC, Immediate Release Aceclofenac. 
1. INTRODUCTION 
Aceclofenac, [2-(2-, 6-dichlorophenylamino) 
phenyl] acetoxyacetic acid) is a nonsteroidal 
anti-inflammatory drug (NSAID) of the phenyl 
acetic acid type that is structurally related to 
diclofenac as shown in Figure 1. Chemically it is 
C16H13Cl2NO4 with a molecular weight of 
354.19 (Martindale, 2002). Aceclofenac is 
indicated for the acute and chronic treatment of 
the signs and symptoms of rheumatoid arthritis, 
osteoarthritis, ankylosing spondylitis and 
scapulohumeral periarthritis (Ballesteros et al., 
1990; Honorato et al., 1990). It is also indicated 
for pain of various etiologies such as 
musculoskeletal pain (e.g. low back pain), dental 
pain or postsurgical pain (Ballesteros et al., 
1990).  
  
Aceclofenac produces its effects by inhibition of 
an enzyme (cycloxygenase) production which is 
essential for the production of inflammatory 
process. It selectively blocks the lipoxygenase 
that inhibit the cox-2 dependant production of 
prostaglandins (Yong et al., 2005; Chandra et al., 
2012). Biotransformation of aceclofenac is 
carried out by cytochrome P-450 2C9 (CYP2C9) 
mediated hydrolysis and hydroxylation to 
diclofenac and 4-hydroxy-aceclofenac 
respectively (Kang et al., 2008). 
After absorption of aceclofenac, the drug is 
progressively hydrolysed to diclofenac in the 
circulation, which accounts for 51% of the 
activity. Aceclofenac is metabolized into a large 
number of compounds; the most important 
metabolite is 4-hydroxyaceclofenac (Bubani, 
1988). It has good analgesic, potent 
anti-inflammatory and antipyretic (Movilia, 
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1989; Yong et al., 2005; Naz et al., 2011; Yadave 
et al., 2009). 
 
 
 
 
Figure 1: Chemical structure of Aceclofenac 
Aceclofenac is absorbed rapidly as unchanged 
drug when taken orally, and its analgesic effect 
can begin within 30min of ingestion (Honorato 
et al., 1990). 
It reaches a peak plasma concentration 1–3h 
after ingestion (Martindale, 2002). Cmax and 
AUC increase proportion-ally in the dose range 
50–150mg (Honorato et al., 1990). When 
aceclofenac is administered to fasting and fed 
healthy volunteers, only the rate but not the 
extent of aceclofenac absorption is affected by 
the presence of food in the gastrointestinal tract. 
The mean plasma elimination half-life is 
approximately 4h; parent compound and its 
metabolites are eliminated primarily (66%) in 
the urine and to a lesser extent in the faeces 
(Honorato et al., 1990; Martindale, 2002).  
A new, simple, fast and validated HPLC method 
was developed for the study of bioequivalence of 
two commercially available brands of 
Aceclofenac 100mg tablets. The aims and 
objectives of this study was to develop and 
standardize an HPLC-UV method for analysis of 
Aceclofenac in plasma and to determine 
bioavailability and bioequivalence of two 
marketed brands of Aceclofenac 100mg tablets in 
healthy human volunteers. 
2. MATERIAL AND METHODS 
2.1 Study Design and Selection of Subjects 
The study was a single dose, randomized with 
single treatment and was completed in a period 
of treatment single dosing. Clinically there was 
no any major medical history of any volunteer 
and they were informed not to take any 
medication for at least 2 weeks before the study. 
Awareness about the aim of the study was clear 
among all volunteers. Before the start of study 
written informed consent was obtained from 
each volunteer. Eighteen healthy human 
volunteers were scheduled to participate in the 
study. Each volunteer was given single dose of 
aceclofenac 100 mg immediate release 
formulation in tablet dosage form orally. Subjects 
with any disorder or illness were not included in 
this study. 
2.2 Experimental Design for Drug Administration 
18 healthy human volunteers were selected for 
bioequivalence study of two formulations of 
aceclofenac drug; drug A (Acemed® ) and drug B 
(Airtal® ). Volunteers were randomly divided 
into two groups and each group was contained 9 
subjects. One group received drug A and second 
group received drug B with 250ml of water after 
an overnight fast (12 hours) by using a 
two-treatment, two-way cross over study design 
in a randomized fashion. A one week washout 
period was given between dosing plan. After the 
6 hours of dosing breakfast was given to each 
subject. Breakfast, lunch and dinner were 
provided to the subjects according to the 
schedule. Each subject receives similar type of 
food. 
2.3 Blood Sampling  
The blood samples were collected by using 
intravenous route. A 22 gauge cannula was 
inserted into vein of forearm and blood is drawn 
by using disposable syringes at zero time before 
drug was given. In the same way blood samples 
were drawn at 0.5,1,2,3,4,5,6,8,10,12 and 24 
hours after the administration of 100mg 
aceclofenac immediate release tablet. 5ml blood 
samples were collected each time and put the 
samples in labeled disposable plastic centrifuge 
tubes containing 100ul of heparin as 
anticoagulant. Immediately after pouring the 
blood samples into these tubes, blood samples 
were centrifuged at 5000 rpm for 10 
minutes .The clear upper plasma layer was 
collected to the labeled sterile glass vials, capped 
them tightly and stored it immediately at -20C0 
until assay. Same procedure was repeated after 
the 7 days of washout period to complete the 
crossover design. 
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2.4 Chromatographic Conditions 
Sykam GmbH HPLC system (Germany) equipped 
with Sykam S2100 solvent delivery system, 
Sykam 4011 thermo controller, Sykam S3210 
UV/VIS detector and Clarity operating software 
(MS-Windows) was used to control and operate 
the instrument. 
For LC Column and Pump different parameters 
were used. The mobile phase consisted of 
53:24:23 mixture of 0.025M Na2HPO4, 
methanol and acetonitrile, respectively. The pH 
of mobile phase was adjusted at 7 with 1:1 
H3PO4 solution at 25oC. The mobile phase was 
filtered through 0.045u membrane filter paper 
and sonicated to degas it. Fresh mobile phase 
was used and prepared daily (Rhim et al., 2008). 
Column used was ODS-C18, Flow rate was kept 
as 1 ml/min. Detection was performed at 
278nm. Internal standard used was diclofenac 
potassium. The blank plasma samples were 
analyzed before the analysis of test and standard 
samples. The response factor was measured by 
the ratio of the peak height of drug to that of the 
internal standard for both standard and test 
samples. The peaks obtained were well defined 
and the retention times for aceclofenac and 
internal standard (diclofenac) was 5.2 ± 0.4 min 
and 4.1 ± 0.2 min, respectively. 
On the basis of chromatographic conditions 
prescribed above, the LOD and LOQ values of 
Aceclofenac were 0.019µg/ml and 0.312µg/ml, 
respectively. A linear relationship was found 
between concentration and the peak height ratio 
in the range of 0.312-20 µg/ml. 
2.5 Evaluation of Pharmacokinetic Parameters 
Thermo Kinetica” version 4.4.1 was used for 
pharmacokinetic analysis by using 
non-compartmental method developed by 
“Thermo Electron Corporation” and by 
“Microsoft Excel” of “Microsoft ® Corporation”. 
Linear trapezoidal rule was used to calculate the 
area under time concentration curve (AUCo-∞) 
by using the same software. Maximum 
aceclofenac concentration in plasma (Cmax) and 
maximum time to these concentrations (Tmax) 
were determined by plasma concentration 
Verses time profiles. Elimination half-life (t1/2) 
was also calculated. 
 
2.6 Statistical Methods 
Standard error of mean (SEM), standard 
deviation (SD) and Mean were determined by 
using descriptive statistical formulas either by 
Kinetica 4.4.1 or MS Excel. Pharmacokinetic 
parameters such as AUCo-t, AUC0-∞ , Tmax, 
Cmax, t1/2, Vd, Ke, Cl and Vss were calculated by 
using kinetic for the purpose of bioequivalence 
analysis. 
3. RESULTS AND DISCUSSION  
The study was a randomized, two treatments, two 
way crossover design, where Aceclofenac in a 
dose of 100 mg of Product A was administered 
to Group A and Aceclofenac 100mg of Product B 
was administered to Group B. After a wash out 
period of 1 week, Group A received Product B 
and Group B received Product A. The Mean ± 
SEM (n=18) bioavailability and pharmacokinetic 
parameters of Aceclofenac Product A and B are 
shown in Table 1. 
For the development of HPLC-UV method for the 
analysis of Aceclofenac, different mobile phases 
with different compositions, pH, flow rates and 
different stationary phases (i.e. columns) were 
used to develop and optimize a new, simple and 
fast method. 
The objectives of the study were to develop, 
standardize a new HPLC-UV analytical method 
to study in vivo pharmacokinetic parameters 
and bioequivalence of two commercially 
available tablet dosage forms containing 
Aceclofenac as active pharmaceutical ingredient. 
The validation of analytical method was carried 
out according to FDA guidelines for 
bio-analytical method validation. Aceclofenac is 
safest drug among NSAID, as there was no any 
harmful effects were observed in all volunteers 
till the end of study. Both products are readily 
absorbed from the gastrointestinal tract and the 
concentration time profile of both products 
shows that both products are bioequivalent. 
After the administration of product A and 
product B, the peak concentration obtained were 
7.69 ± 0.36 µg/ml and 6.82 ± 0.13 µg/ml for 
aceclofenac at 3.0 ± 0.14 h and 2.94 ± 0.19 h 
respectively. Clearance is one of the parameter 
that determines the maintenance dose rate 
required to achieve a target plasma 
concentration and therefore, effect at steady 
state. The total body clearance (ClT) (Mean ± 
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SEM) values of drug A (Acemed®  and drug B 
(Airtal® ) were 2.27 ± 0.10 L/h and 2.18 ± 0.06 
L/h. The value of total body clearance has not 
been reported in literature. elimination rate 
constant (Ke) (Mean ± SEM) of drug A 
(Acemed® ) and drug B (Airtal® )) was found as 
0.22 ± 0.004 h-1 and 0.23 ± 0.002 h-1, 
respectively . As F- value for Relative 
Bioavailability or Comparative bioavailability lies 
between 0.8 and 1.25 i.e. 1.04, hence both 
products of Aceclofenac are bioequivalent 
(Bourne, 2002). 
After log-transformation of the data, there was 
no significant difference observed statistically 
between the two products of aceclofenac. 90% 
confidence intervals shows that the ratios of 
AUCo-∞ , AUCo-t, (Cmax) of two aceclofenac 
products lie in the range of 80%-125% that is 
acceptable according to the FDA guideline 
Table 1: Comparison of Mean ± SEM (n=18) bioavailability and pharmacokinetic parameters of 
Aceclofenac Product A and B administered in a dose of 100 mg 
S. No. 
 
Bio-parameters Product A  
 
Product B P-Value 
1 AUCo-∞ µg. h
2/ml 45329.97 ± 2138.87 43589.97 ± 0.1842 P = 0.250 
2 AUC0-t µg. h/ml 45332.79 ± 2096.77 43842.56 ± 1048.95 P = 0.285 
3 C max µg/ml 7.69 ± 0.36 6.82 ± 0.13 P = 0.08 
4 T max  (hr.) 3.0 ± 0.14 2.94 ± 0.19 P = 0.369 
5 MRT (hr.) 5.75 ± 0.08 5.76 ± 0.06 P = 0.489 
6 Vd  L/Kg 10.10 ± 0.52 9.97 ± 0.22 P = 0.413 
7 t ½  (h) 3.14 ± 0.08 3.01 ± 0.024 P = 0.065 
8 Ke 1/h 0.22 ± 0.005 0.23 ± 0.002 P = 0.045 
9 Cl mL/min/Kg 2.27 ± 0.10 2.18 ± 0.06 P = 0.190 
10 Ka l/h 9.29 ± 0.04 9.28 ± 0.02 P = 0.374 
 
4. CONCLUSION 
All Pharmacokinetic parameters have similar 
values for Aceclofenac 100mg tablet Acemed and 
Airtal. Therefore, on the basis of above study it is 
concluded that both Aceclofenac 100mg drug A 
(Acemed® ) and drug B (Airtal® )) is 
bioequivalent. Both products have the same 
efficacy and can be used alternative to each 
other. 
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